Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Rises By 117.6%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 3,700 shares, a growth of 117.6% from the February 28th total of 1,700 shares. Based on an average trading volume of 10,700 shares, the short-interest ratio is currently 0.3 days. Approximately 1.1% of the shares of the stock are sold short.

Scinai Immunotherapeutics Price Performance

Shares of NASDAQ:SCNI traded down $0.50 on Friday, reaching $2.90. 144,912 shares of the company were exchanged, compared to its average volume of 276,915. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average of $3.43 and a 200-day moving average of $3.45. Scinai Immunotherapeutics has a 1-year low of $2.23 and a 1-year high of $8.92. The firm has a market cap of $2.47 million, a price-to-earnings ratio of -0.01 and a beta of 2.36.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.